Talazoparib (oral 1 mg, once daily [QD]) is approved in the US, EU, and other countries as monotherapy for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer with a germline BRCA1/2 mutation [15, 16], and is under investigation in other tumor types [17, 18]. This evidence concerns the gene ERBB2 and breast carcinoma.